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INTRODUCTION
In the last decade, the concepts of endocrinology and 
immunology have been dramatically changed. Previously, 
endocrine cells have been regarded as the major source of 
hormones, whereas immune cells – the major source of 
cytokines and chemokines. However, the adipose tissue 
may turn out to be at least as important for the secretion of 
both hormones (1-3) and cytokines (4). The discovery of the 
adipocyte-secreted cytokine leptin (1) was a trigger for further 
adipocentric studies on endocrine, paracrine and intracrine 
functions of adipose tissue. Accumulating basic and clinical 
studies indicate that adipose tissue cells (adipocytes, matrix 
cells, stromovascular cells, macrophages, and mast cells) 
synthesize and release a diverse range of multifunctional 
molecules designated adipokines (1-8). Due to recent advance 
in genomic and proteomic approaches, the secretory proteome 
of adipose cells (adipokinome) (5) is constantly being enriched 
with newly identified adipokines (9-16). Further, the whole
spectrum of adipose secretory products (secretome) (5) is 
not limited to adipokines, but also includes non-proteins 
such as prostaglandins, fatty acids, monobutyrin, and steroid 
hormones. This intellectual growth process defined a new
field of study, adipobiology (16): the study of the molecular
and cellular biology of the normal and diseased adipose tissue 
and related disorders.
Here we present an updated overview of adipobiology 
of chronic low-grade inflammation in atherosclerotic cardio-
vascular disease, thyroid-associated (Graves’) ophthalmopathy, 
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inflammatory bowel disease, and breast cancer. We propose
that the pathogenesis of these disorders may be influenced
by competing stimulatory and inhibitory effects mediated 
by adipokines. Adipose-produced inflammation-related non-
proteins, such as prostaglandins, steroid hormones and nitric 
oxide, are out of the scope of present Dance Round. 
ADIPOSE TISSUE
In humans, particularly well developed is the white adipose 
tissue. It is partitioned into two large depots (mesenteric and 
subcutaneous), and many small visceral depots associated 
with heart, blood vessels, major lymph nodes, ovaries, 
mammary glands, eyes, and bone marrow. The presence 
of adipose tissue-associated stem cells throughout life has 
been revealed; they may differentiate into osteoblasts, 
chondrocytes, adipocytes, cardiomyocytes, and neural cells 
(17 and references therein), thus opening novel perspectives 
for restorative medicine including in diseases herein discussed 
such as heart failure and fistulising Crohn’s disease. Another
adipose tissue subtype, brown adipose tissue, is very scarce 
and probably less functional in adult humans. Through the 
inner mitochondrial membrane protein uncoupling protein-1, 
brown adipose tissue is mostly involved in theromogensis, 
and less in inflammation.
ADIPOKINES IN INFLAMMATION-RELATED DISEASES
Inflammation is an essential biological response aiming at
recovering from injury, wound healing being a paradigm of 
such a homeostatic phenomenon. However, what begins as a 
protective response, in excess becomes a damaging process. 
Hence, the inflammation, and particularly chronic low-grade
inflammation, is increasingly recognized as the underlying 
basis of a significant number of diseases. Recent genomic
studies in human white adipose tissue revealed that a panel 
of pro-inflammatory molecules were upregulated in obese
compared to lean subjects (9,10 and references therein). Of 
note, caloric restriction diet (9) and surgery-induced weight 
loss (10) improved the inflammatory profile of obese subjects
via a downregulation of pro-inflammatory and upregulation
of anti-inflammatory adipokines. These analyses as well as
others (18-23) support the hypothesis that adipose tissue-
secreted signaling molecules may be potent modulators 
of inflammation in various diseases (Table 1). The field of
adipobiology of inflammation has thus attracted an increasing
attention. 
Epicardial adipose tissue and cardiovascular disease
Recently, the paracrine secretory activity of the small visceral 
adipose depots has, at long last, become a focus in the 
adipobiology of inflammation, including in cardiovascular
disease. An example of such depot is epicardial adipose tissue 
(EAT), which may be involved in possible paracrine trans-
mission of protective and/or pathogenic signals targeted to 
the heart and associated coronary arteries.  Epicardial adipose 
tissue is a visceral fat depot in the heart, especially in the 
regions of the right-ventricular free wall and left-ventricular 
apex. This neglected tissue is now appreciated as a potent 
producer of various inflammation-related adipokines (24-28). 
An essential subtype of EAT is the subepicardial adipose 
tissue surrounding the most atherosclerosis-prone portions 
of the coronary artery, that is, the most proximal part of its 
left anterior descending branch. Conceptually, the role of an 
outside-to-inside signaling pathway (perivascular adipose 
tissue-adventitia-media-intima signaling), recently dubbed 
vasocrine signaling (29), became at the focus of several recent 
studies in cardiovascular research (24-33). Vascular processes 
that could be controlled by such paracrine signals include (i) 
artery relaxation (30,31 for adipose-derived relaxing factor, 
ADRF), (ii) smooth muscle cell growth and migration (32), 
and also (iii) coronary atherosclerosis (24-28) and other heart 
diseases (through EAT-myocardium signaling). These topics 
are reviewed by Montani et al (32) and Iacobellis et al  (33). 
In perspective, using EAT-depleted mice and ADRF-deficient
mice may further our knowledge of EAT and perivascular 
adipose tissue, respectively. 
A major lesson learned from these adipocentric studies 
is that EAT should no longer be neglected in studies of 




Type 2 diabetes (29,63)
Atherosclerosis  (6,21-28,32,33)
Thyroid-associated ophthalmopathy (35-37) 
Inflammatory bowel diseases (38,39,41,58,61)
Mesenteric panniculitis (61)




Chronic obstructive pulmonary disease (66)
HIV-associated adipose redistribution syndrome (67)
End-stage renal disease  (68)
Psoriasis (?), Scleroderma (?)
* References are indicated in parentheses.
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cardiovascular disease. Accordingly, echocardiographic 
assessment of EAT could be a simple and practical tool for 
cardiovascular risk stratification (33). In coronary artery 
bypass grafting, where the surgeon has to make a decision 
how to handle the perivascular adipose tissue of the grafted 
vessel, it should be considered that tissue is a source of ADRF 
(30,31), whereas perioperative graft vasospasm remains a 
concern. Further, the human anterior epicardial fat pad that 
contains parasympathetic ganglia is often dissected during 
coronary artery bypass surgery. However, preservation of this 
tissue may decrease the incidence of postoperative arterial 
fibrilations (34).
Orbital adipose tissue and thyroid-associated 
ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) has an auto-
immune pathogenesis possibly related to the thyrotropin 
receptor (35-37). The symptoms of TAO result from 
inflammation/fibrosis and accumulation of orbital adipose 
tissue. Immunohistochemical analysis of orbital tissue biopsies 
from TAO patients demonstrates that the thyrotropin receptor 
is expressed in fibroblast-like cells, accompanied by mast cell
infiltrates (35). Further, transforming growth factor-β inhibits 
whereas interleukin-6 (IL-6) stimulates thyrotropin receptor 
expression (36), suggesting that the pathogenesis of TAO 
may be influenced by competing inhibitory and stimulatory
adipokine effects within the orbit. 
Mesenteric adipose tissue and inflammatory bowel
disease
A characteristic feature of inflammatory bowel diseases (IBD),
such as Crohn’s disease and ulcerative colitis, is mesenteric 
adipose tissue hypertrophy. Dysregulation of adipokine 
secretion by this tissue is critically involved in the pathogenesis 
of IBD. Under healthy conditions, the intestinal mucosa is in 
a state of “controlled inflammation” regulated by a delicate
balance of pro-inflammatory factors, e.g. tumor necrosis factor-
α (TNF-α), leptin, interferon-γ, IL-1, IL-6, and IL-12 and anti-
inflammatory factors, e.g. adiponectin, IL-4, IL-10, and IL-11
(38; reviewed in 39). The pivotal pathogenic role of TNF-α in 
IBD is recently targeted in the therapy applying biologicals, 
for example, infliximab, a monoclonal antibody against TNF-α 
(38). Further, a recent study demonstrated an enhanced mRNA 
expression for nerve growth factor (NGF) and its receptor 
tyrosine kinase A, and an increased NGF-immunoreactivity in 
intestinal cells in Crohn’s disease and ulcerative colitis (40); 
this calls for similar studies in the inflamed mesenteric adipose
tissue in IBD, since NGF is implicated in other inflammatory
diseases (5,24). Whether omentin, a recently discovered 
adipokine (41), could be embodied in the pathogenesis of IBD 
remains to be evaluated. 
Mammary adipose tissue and breast cancer
It is known that inflammation can promote tumorigenesis. 
There is compelling evidence indicating that both normal 
mammary gland development and breast cancer growth 
depend, in part, on microenvironment of which adipose tissue 
is a key component (15 and references therein).  Recently, Celis 
et al (15) provided the most extensive proteomic analysis of 
the mammary adipose secretome in high risk breast cancer 
patients. Adipose fibroblasts are also important cellular 
component of breast cancer microenvironment. These cells are 
one of the major extragonadal sources of estrogen secretion 
in postmenopausal women. The key enzyme in estrogen 
synthesis is aromatase cytochrome P450 (P450arom) which 
converts androgens to estrogens. In breast cancer, one of the 
most aggressive human cancer, intratumoral proliferation of 
adipose fibroblasts is accompanied by an increased P450arom
expression by these cells, leading to proliferation of breast 
epithelial cells (42). Notably, NGF stimulates breast cancer 
cell proliferation  (43,44), and the antiestrogen drug tamoxifen 
inhibits NGF-mediated breast cancer cell proliferation through 
inhibition of NGF TrkA receptor (43). These data suggest a 
novel, NGF-mediated mechanism in the action of an old drug, 
tamoxifen, in breast cancer pharmacotherapy. Further, NGF 
can be produced by both adipocytes (5,15,24) and mast cells 
(45), and these latter cells commonly associate with breast 
cancer (46). These findings open possibilities for an adipose
NGF-/mast cell-oriented therapy of breast cancer (16), and 
pressingly call for studies on adipopharmacology of this 
neoplastic disorder.
CONCLUSION
The fattening of humans and the associated emergence of 
obesity and related diseases are among the major epidemiologic 
events at present. Their control requires a greater understanding 
of the pathogenesis of these diseases. Since they are associated 
with chronic low-grade inflammation affecting adipose tissue,
current studies center on the adipobiology of inflammation.
Thus adipose tissue is increasingly appreciated as a major 
source of and target for inflammatory signals. Since the
actions of adipokines are complex and diverse, we need to 
design novel studies to determine how these molecules affect 
various processes triggered by inflammation.At a mechanistic
level, promotion of anti-inflammatory and suppression of
pro-inflammatory adipokine-mediated signals may result
in an improvement of inflammatory disease therapy (Table
2). Supposedly, the present challenge is to cultivate an 
86
Biomed Rev 16, 2005
Chaldakov, Tonchev, Georgieva, Ghenev, and Stankulov
adipocentric thinking about how we can make adipokines work 
for the benefit of patients with chronic low-grade inflammatory
diseases. 
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Nerve growth factor (?) 
Metallothionein-1,-2




Calcitonin gene-related peptide 
Tumor necrosis factor-α









* For references, see the text (2,5,15,16,47-68). Also note that exercise stimulates skeletal muscle endocrine secretion of anti-
inflammatory myokines which interact with adipose tissue (56,57), whereas cigarette smoking upregulates pro-inflammatory
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